| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 4.857 | 19.078 | 12.182 | 21.892 | 27.688 | 45.469 | 50.392 | 48.806 | 45.605 |
| Total Income - EUR | - | 4.857 | 19.078 | 12.182 | 21.892 | 27.688 | 45.469 | 50.417 | 53.317 | 45.605 |
| Total Expenses - EUR | - | 4.394 | 14.448 | 9.805 | 16.897 | 20.546 | 39.686 | 45.992 | 49.303 | 50.929 |
| Gross Profit/Loss - EUR | - | 463 | 4.629 | 2.377 | 4.996 | 7.142 | 5.783 | 4.424 | 4.014 | -5.323 |
| Net Profit/Loss - EUR | - | 318 | 4.057 | 2.012 | 4.339 | 6.311 | 4.582 | 3.138 | 3.359 | -5.323 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Sanfer Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 540 | 402 | 269 | 273 | 195 | 119 | 69 | 30 | 57 |
| Current Assets | - | 3.857 | 6.953 | 11.527 | 16.587 | 23.504 | 25.276 | 27.473 | 22.832 | 19.089 |
| Inventories | - | 2.309 | 2.989 | 1.395 | 2.864 | 5.034 | 5.957 | 12.747 | 9.680 | 5.744 |
| Receivables | - | 0 | 431 | 438 | 429 | 0 | 259 | 61 | 0 | 96 |
| Cash | - | 1.548 | 3.534 | 9.694 | 13.294 | 18.470 | 19.061 | 14.664 | 13.152 | 13.250 |
| Shareholders Funds | - | 362 | 4.413 | 6.344 | 10.559 | 16.671 | 18.756 | 21.952 | 19.399 | 13.312 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 4.034 | 2.943 | 5.452 | 6.300 | 7.028 | 6.639 | 5.589 | 3.462 | 5.835 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4729 - 4729" | |||||||||
| CAEN Financial Year |
4729
|
|||||||||
Comments - Sanfer Pharm Srl